返回搜尋
慧智 2025Q2 法人說明會
6615上櫃
法人說明會
慧智 2025Q2 法說會簡報重點與營運摘要

慧智基因 SOFIVA GENOMICS (6615) 114Q2 法說會簡報

Company Overview

  • Company Name: 慧智基因 SOFIVA GENOMICS (Sofiva Genomics Co., Ltd.)
  • Stock Code: 6615
  • Event: 法人說明會 (Investor Conference)
  • Date of Presentation: 114/06/25 (June 25, 2025 - ROC Calendar Year)
  • Chairman: 蘇怡寧 (Yi-Ning Su, MD. Ph.D)
  • Slogan: Details Make Differences
  • Contact Information:
    • Website: www.sofiva.com.tw
    • Tel: +886-2-2382-6615
    • Fax: +886-2-2382-6617
    • Address: 台北市100中正區寶慶路27號 (No. 27, Baoqing Rd., Zhongzheng Dist., Taipei City 100)

Disclaimer

  • 本資料除提供歷史信息外,部份內容若涉及未來展望的表述,因受到風險及不確定因素影響,實際結果與表述內容將可能明顯不同。投資人應自行判斷與控制風險。

Business Segments and Product/Service Offerings

3.1. Dual-Axis Development (雙主軸發展)

  • 母胎兒醫學 (Maternal-Fetal and Pediatric Medicine)
  • 癌症精準醫學 (Precision Oncology)

3.2. Gene Testing Product Lines (基因檢測產品線)

  • 生殖醫學 (Reproductive)
    • Unit: 人工生殖中心 (Assisted Reproductive Technology Center)
    • Population: 試管嬰兒 (IVF babies), 胚胎檢測 (Embryo testing)
    • Specific Tests:
      • 胚胎著床前單基因檢測 PGT-M
      • 胚胎著床前染色體篩檢 PGT-A
      • 非侵入性胚胎著床前染色體篩檢 niPGT-A
  • 產前-孕前 (Prenatal-Pre-pregnancy)
    • Unit: 婦產科 (Obstetrics and Gynecology)
    • Population: 備孕夫妻 (Couples preparing for pregnancy), 懷孕夫妻(胎兒) (Pregnant couples (fetus))
    • Specific Tests:
      • 非侵產前染色體篩檢 NIPS
      • 全方位複合式晶片檢測 Array CGH
      • 產前細胞染色體檢查
      • 帶因篩檢 Carrier Scan:
        • 脊髓性肌肉萎縮症基因檢測-SMN基因
        • X染色體脆折症基因檢測-FMR1基因
        • 海洋性貧血基因檢測-HBA及HBB基因
        • 葉酸代謝基因檢測-MTHFR基因
  • 新生兒 (Newborn)
    • Unit: 小兒科、新生兒科 (Pediatrics, Neonatology)
    • Population: 新生兒 (Newborns), 幼童 (Young children)
    • Specific Tests:
      • 新生兒基因篩檢 Baby Scan
      • 感覺神經性聽損基因檢測
      • 先天中樞性換氣不足症候群基因檢測
      • 先天性巨細胞病毒感染檢測
      • 異位性皮膚炎過敏基因檢測-FLG基因
  • 癌症 (Cancer)
    • Unit: 與癌症相關科別 (Cancer-related departments)
    • Population: 所有族群 (All populations) (癌前、癌友) (Pre-cancer, Cancer patients)
    • Specific Tests:
      • 癌監控基因檢測 Cancer Monitor
      • 癌症基因篩檢 Cancer Scan
      • 癌風險基因檢測v1.0/v2.0
      • 人類乳突病毒篩檢(HPV)
  • 精準用藥 (Precision Medicine)
    • Unit: 與癌症用藥、罕病用藥相關科別 (Departments related to cancer drugs, rare disease drugs)
    • Population: 所有族群 (All populations)
    • Specific Tests:
      • BRCA1/2基因檢測
      • HRD檢測
      • CGP基因檢測
      • 子宮內膜癌基因分型
      • 攝護腺癌基因檢測
  • 罕見疾病 (Rare Disease)
    • Unit: 基因檢測需求單位 (Gene testing demand units)
    • Population: 所有族群 (All populations)
    • Specific Tests:
      • 聽損基因檢測 v1.0/v2.0/v3.0
      • 軟骨發育不全(侏儒症)
      • 成骨發育不全(玻璃娃娃)
      • 裘馨氏肌肉萎縮症
      • 威爾森氏症
      • 馬凡氏症候群
      • 全外顯子定序基因檢測

Strategic Initiatives and Plans

4.1. NHI Reimbursement (健保給付)

  • NGS Testing Reimbursement (符合NGS檢測給付):
    • Scope: 超過十種檢測 符合各癌別健保給付條件
    • Inclusion: 14類實體腫瘤 and 5類血液腫瘤
    • Reimbursement Amounts:
      • BRCA基因檢測: 給付10000元
      • 小套組 (≤100基因): 給付20000元
      • 大套組 (>100基因): 給付30000元
    • Data Upload: NGS test results must be uploaded to the NHI Administration for future drug matching.
    • Approved Tests: Details included for various panels and conditions.

4.2. Layout for Health Checkup Market (佈局健檢市場)

  • Overall Strategy: 全方位精準健康
  • Target Groups & Focus:
    • 備孕 (Pre-pregnancy)
    • 女性 (Women)
    • 男性 (Men)
    • 長者 (Elderly)
  • Products for Health Checkup Market:
    • Include various gene screening and cancer risk assessments.

4.3. Reproductive Market Trends (生殖市場趨勢)

  • Trend: 高齡生育需求提升
    • Data provided for maternal age distribution over the years.

Financial Highlights and Key Metrics

5.1. Summary Income Statement for Recent Three Years (單位: 新台幣仟元)

項目 (Item)111年 (2022)112年 (2023)113年 (2024)
營業收入 (Operating Revenue)495,775466,797453,312
營業毛利 (Gross Profit)148,988129,908135,661
毛利率 (Gross Margin)30.05%27.83%29.93%
營業利益 (Operating Income)3,787-15,882-3,373
營業外收入及支出 (Non-operating Income and Expenses)43,56224,78526,988
稅前淨利 (Profit Before Tax)47,3498,90323,615
本期淨利 (Net Profit for the Period)43,15311,92319,128
每股盈餘(元) (Earnings Per Share (NT$))2.000.540.86

5.2. Operating Revenue for Recent 10 Quarters (單位: 新台幣仟元)

  • Details for quarterly revenue over recent years.

5.3. Operating Revenue for Recent 6 Months (單位: 新台幣仟元)

  • Recent operating revenues month by month.

5.4. Investment Performance (轉投資績效) - Investee: 禾馨股份有限公司 (Herhsing Co., Ltd.)

  • Summary of investment performance over the last three years for the investee.

Key Charts, Graphs, and Data Points

6.1. NGS NHI Reimbursement - National Declaration Statistics

  • Total Declarations: 1,019件
    • Large Panel: 423件
    • Small Panel: 577件

6.2. Cancer: Top Ten Causes of Death

  • Statistics on cancer deaths published by year.

6.3. Health Checkup Market Size

  • User statistics and service utilization rates by age groups.

6.4. Alzheimer's Disease Prevalence and APOE Risk

  • Prevalence rates and risk assessments based on APOE genotype.

6.5. Maternal Age Distribution

  • Percentages of mothers in specific age groups over the years.

6.6. PGT-A Demand Growth - Annual Treatment Cycles

  • Annual treatment cycle data to illustrate demand growth.

🤖 FinmoAI

BETA
AI 驅動 • 法說會分析
法說會逐字稿
生成重點摘要和投資要點
挖掘潛在投資機會
體驗 AI 智能分析

📱 即時通知服務

加入我們的 Telegram 機器人 @diveinvest_bot,每晚 8 點自動推送最新法說會簡報。

加入 Telegram 通知